1. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
- Author
-
Umemura M, Suda G, Tsukamoto S, Ebata K, Takahash S, Sasaki T, Nakajima S, Hirata K, Ozasa M, Takano M, Katagiri M, and Sakamoto N
- Subjects
- Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Genotype, Humans, Leucine administration & dosage, Male, Middle Aged, Prednisone therapeutic use, Proline administration & dosage, Pyrrolidines, RNA, Viral blood, RNA, Viral genetics, Rituximab therapeutic use, Sustained Virologic Response, Vincristine therapeutic use, Viral Load drug effects, Aminoisobutyric Acids administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antiviral Agents administration & dosage, Benzimidazoles administration & dosage, Cyclopropanes administration & dosage, Hepacivirus genetics, Hepatitis C complications, Hepatitis C drug therapy, Lactams, Macrocyclic administration & dosage, Leucine analogs & derivatives, Lymphoma, Large B-Cell, Diffuse complications, Lymphoma, Large B-Cell, Diffuse drug therapy, Proline analogs & derivatives, Quinoxalines administration & dosage, Sulfonamides administration & dosage
- Abstract
Background: In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies., Case Presentation: We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion., Conclusion: On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.
- Published
- 2021
- Full Text
- View/download PDF